Keyphrases
Gemcitabine
100%
Potentiation
100%
Human Breast Cancer Cells
100%
Sequence-dependent
100%
Flavopiridol
100%
F-group
42%
Apoptosis
28%
Growth Inhibition
14%
Cyclin-dependent Kinase Inhibitor
14%
Breast Cancer Cell Lines
14%
Protein Kinase
14%
Biological Activity
14%
Flow Cytometry
14%
Estrogen Receptor Status
14%
Phase I Clinical Trial
14%
Treatment Strategy
14%
Caspase-3
14%
Gastrointestinal
14%
Anti-apoptotic Bcl-2
14%
MTT Assay
14%
Clinical Trial Design
14%
Phase II Clinical Trial
14%
Pro-apoptotic
14%
Preclinical Evaluation
14%
Estrogen Receptor-positive
14%
P21Cip1
14%
MCF-7
14%
Cell Counting
14%
Cytotoxic Concentration
14%
Poly(ADP-ribose) Polymerase
14%
MDA-MB-231 Cells
14%
Cytotoxic Therapy
14%
Estrogen Receptor-negative
14%
Human Breast Cancer Cell Lines
14%
Immunology and Microbiology
Cancer Cell
100%
Upregulation
100%
Breast Cancer Cell Line
100%
Programmed Cell Death
100%
Cell Line
50%
Caspase
50%
Cycline
50%
Growth Inhibition
50%
Bcl-2
50%
Cytotoxic Concentration
50%
Biological Activity
50%
Protein Kinase C
50%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Gemcitabine
100%
Flavopiridol
100%
Clinical Trial
42%
Estrogen Receptor
42%
Cyclin Dependent Kinase Inhibitor
14%
Antiapoptotic
14%
Biological Activity
14%
Protein Kinase C
14%
Caspase 3
14%
Flow Cytometry
14%
Cytotoxic Chemotherapy
14%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase
14%